Patent Assignment
Reel/Frame 073949/0722
Notice of Grant of Security Interest in Patents
Recorded: 2025-12-15
Pages: 17
Assignors
GENMAB HOLDING B.V.
Executed: 2025-12-12
GENMAB A/S
Executed: 2025-12-12
GENMAB B.V.
Executed: 2025-12-12
Assignee
WILMINGTON TRUST, NATIONAL ASSOCIATION
99 WOOD AVENUE SOUTH, SUITE 1000, ATTENTION: GENMAB NOTES ADMINISTRATOR, ISELIN, NEW JERSEY, 08830
Covered Properties
(178)
Antibodies
Antibodies
Antibodies
Antibodies
Application:
18/617,483 →
Publication:
US US20240392032A1
Antibodies
Application:
17/204,604 →
Publication:
US US20210292418A1
Antibodies
Antibodies
Application:
19/068,872 →
Publication:
US US20250340647A1
Antibodies Against CD38 for Treatment of Multiple Myeloma
Application:
18/235,550 →
Publication:
US US20240228662A9
Antibodies Against CD38 for Treatment of Multiple Myeloma
Antibodies Against CD38 for Treatment of Multiple Myeloma
Antibodies Against Human CD38
Antibodies Against Human CD38
Antibodies Against Human CD38
Antibodies Against Pd-L1
Application:
18/539,509 →
Publication:
US US20240317861A1
Antibodies Binding Axl
Antibodies Binding Axl
Antibodies Binding Axl
Antibodies Binding Axl
Antibodies Binding Axl
Antibodies Binding to CD30 and CD3
Antibodies Binding to CD30 and CD3
Application:
18/478,711 →
Publication:
US US20240228641A9
Antibodies Binding to Fibroblast Activation Protein Alpha and Death Receptor 4
Antibodies Binding to Fibroblast Activation Protein Alpha and Death Receptor 4
Application:
19/229,535 →
Publication:
US US20260028427A1
Antibodies Capable of Binding to ROR2 and Bispecific Antibodies Binding to ROR2 and CD3
Application:
18/029,472 →
Publication:
US US20230365714A1
Antibodies for Use in Therapy
Application:
17/795,318 →
Publication:
US US20230087164A1
Antibody Therapy
Application:
18/023,808 →
Publication:
US US20230310599A1
Antibody Variants Having Modifications In The Constant Region
Antibody Variants Having Modifications in the Constant Region
Anti-CD70 Antibodies, Conjugates Thereof and Methods of Using the Same
Application:
18/556,240 →
Publication:
US US20250066490A1
Anti-Tissue Factor Antibody-Drug Conjugates and Their Use in the Treatment of Cancer
Application:
16/978,539 →
Publication:
US US20210030888A1
Anti-Tissue Factor Antibody-Drug Conjugates and Their Use in the Treatment of Cancer
Application:
18/010,783 →
Publication:
US US20230263902A1
Axl Antibody-Drug Conjugates for Use in Treating Cancer
Application:
17/628,382 →
Publication:
US US20220273809A1
Axl-Specific Antibodies for Cancer Treatment
Application:
17/046,199 →
Publication:
US US20210070869A1
Axl-Specific Antibody-Drug Conjugates for Cancer Treatment
Application:
16/891,796 →
Publication:
US US20200397913A1
Axl-Specific Antibody-Drug Conjugates for Cancer Treatment
Application:
17/957,302 →
Publication:
US US20230321261A1
Bispecific and Multispecific Antibodies and Method for Isolation of Such
Bispecific Antibodies Against CD3 and CD20
Application:
18/855,842 →
Publication:
US US20250304689A1
Bispecific Antibodies Against CD3 and CD20
Bispecific Antibodies Against CD3 and CD20
Application:
16/702,996 →
Publication:
US US20200199231A1
Bispecific Antibodies Against CD3 and CD20
Bispecific Antibodies Against CD3 and CD20
Bispecific Antibodies Against CD3 and CD20 for Treating Chronic Lymphocytic Leukemia
Bispecific Antibodies Against CD3 and CD20 for Treating Chronic Lymphocytic Leukemia
Application:
18/025,202 →
Publication:
US US20230312757A1
Bispecific Antibodies Against CD3 and CD20 for Treating Richter's Syndrome
Application:
18/500,673 →
Publication:
US US20240174761A1
Bispecific Antibodies Against HER2
Application:
18/596,319 →
Publication:
US US20250066506A1
Bispecific Antibodies Against HER2 and CD3
Bispecific Antibodies and Methods for Production Thereof
Bispecific Antibodies and Methods for Production Thereof
Method of Treating Cancer by Administering an Antibody Which Binds to 5T4
Bispecific Antibody Against CD3 and CD20 in Combination Therapy for Treating Diffuse Large B-Cell Lymphoma
Bispecific Antibody Against CD3 and CD20 in Combination Therapy for Treating Diffuse Large B-Cell Lymphoma
Application:
17/559,965 →
Publication:
US US20220112309A1
Bispecific Antibody Against CD3 and CD20 in Combination Therapy for Treating Diffuse Large B-Cell Lymphoma
Bispecific Antibody Against CD3 and CD20 in Combination Therapy for Treating Diffuse Large B-Cell Lymphoma
Application:
18/025,203 →
Publication:
US US20240034812A1
Bispecific Antibody Against CD3 and CD20 in Combination Therapy for Treating Diffuse Large B-Cell Lymphoma
Application:
18/025,206 →
Publication:
US US20230355753A1
Bispecific Antibody Against CD3 and CD20 in Combination Therapy for Treating Diffuse Large B-Cell Lymphoma
Application:
18/025,208 →
Publication:
US US20230312759A1
Bispecific Antibody Against CD3 and CD20 in Combination Therapy for Treating Diffuse Large B-Cell Lymphoma
Application:
18/160,386 →
Publication:
US US20230241211A1
Bispecific Antibody Against CD3 and CD20 in Combination Therapy for Treating Diffuse Large B-Cell Lymphoma
Application:
18/160,391 →
Publication:
US US20230303693A1
Bispecific Antibody Against CD3 and CD20 in Combination Therapy for Treating Diffuse Large B-Cell Lymphoma
Application:
18/500,799 →
Publication:
US US20240301078A1
Bispecific Antibody Against CD3 and CD20 in Combination Therapy for Treating Diffuse Large B-Cell Lymphoma
Application:
18/833,261 →
Publication:
US US20250115665A1
Bispecific Antibody Against CD3 and CD20 in Combination Therapy for Treating Diffuse Large B-Cell Lymphoma
Application:
18/833,267 →
Publication:
US US20250101102A1
Bispecific Antibody Against CD3 and CD20 in Combination Therapy for Treating Follicular Lymphoma
Bispecific Antibody Against CD3 and CD20 in Combination Therapy for Treating Follicular Lymphoma
Bispecific Antibody Against CD3 and CD20 in Combination Therapy for Treating Follicular Lymphoma
Application:
18/025,204 →
Publication:
US US20230312758A1
Method for Treating Follicular Lymphoma by Administering Epcoritamab, or Biosimilar Therof, Rituximab and Bendamustine
Application:
18/025,205 →
Publication:
US US20230357440A1
CD38 Antibodies and Uses Thereof
Application:
19/125,633 →
Publication:
US US20250382378A1
CD70 Antibody Drug Conjugates and Methods of Using the Same
Application:
19/123,878 →
Publication:
US US20260083853A1
Combination Treatment of CD38-Expressing Tumors
Combination Treatment of CD38-Expressing Tumors
Application:
19/242,063 →
Publication:
US US20260207740A1
Egfr and C-Met Bispecific Binding Agents, Conjugates Thereof and Methods of Using the Same
Application:
19/065,063 →
Publication:
US US20250381289A1
FOLR1 Binding Agents, Conjugates Thereof and Methods of Using the Same
Application:
18/554,745 →
Publication:
US US20240209080A1
Formulation for Antibody and Drug Conjugate Thereof
Formulations of CD38 Antibodies and Uses Thereof
Application:
17/792,268 →
Publication:
US US20230272105A1
Heterodimeric Antibody Fc-Containing Proteins and Methods for Production Thereof
Heterodimeric Antibody Fc-Containing Proteins and Methods for Production Thereof
Heterodimeric Antibody Fc-Containing Proteins and Methods for Production Thereof
Heterodimeric Antibody Fc-Containing Proteins and Methods for Production Thereof
Application:
18/507,869 →
Publication:
US US20240209117A1
Highly Purified Epcoritamab Compositions
Application:
18/664,757 →
Publication:
US US20240400685A1
Highly Purified Epcoritamab Compositions
Application:
19/484,403 →
Human Antibodies Against Tissue Factor and Methods of Use Thereof
Human Antibodies Against Tissue Factor and Methods of Use Thereof
Human Antibodies Against Tissue Factor and Methods of Use Thereof
Application:
19/077,379 →
Publication:
US US20250340669A1
Human Antibodies and Antibody-Drug Conjugates Against CD74
Human Antibody Drug Conjugates Against Tissue Factor
Human Antibody Drug Conjugates Against Tissue Factor
Human Antibody Drug Conjugates Against Tissue Factor
Application:
18/526,959 →
Publication:
US US20240294661A1
Human Monoclonal Antibodies Against CD20
Human Monoclonal Antibodies Against CD20
Human Monoclonal Antibodies Against CD25
Humanized or Chimeric CD3 Antibodies
Humanized or Chimeric CD3 Antibodies
Humanized or Chimeric CD3 Antibodies
Humanized or Chimeric CD3 Antibodies
Humanized or Chimeric CD3 Antibodies
Application:
16/582,428 →
Publication:
US US20200123255A1
Humanized or Chimeric CD3 Antibodies
Humanized or Chimeric CD3 Antibodies
Humanized or Chimeric CD3 Antibodies
Application:
17/739,940 →
Publication:
US US20220389101A1
Humanized or Chimeric CD3 Antibodies
Application:
18/109,708 →
Publication:
US US20230374131A1
Inert Format
Inert Format
Inert Format
Application:
17/950,350 →
Publication:
US US20230322947A1
Linkers, Drug Linkers and Conjugates Thereof and Methods of Using the Same
Application:
18/227,830 →
Publication:
US US20240207429A1
Linkers, Drug Linkers and Conjugates Thereof and Methods of Using the Same
Application:
19/146,796 →
Publication:
US US20260034237A1
Linkers, Drug Linkers and Conjugates Thereof and Methods of Using the Same
Application:
19/146,799 →
Publication:
US US20260034238A1
Lyophilized Anti-Tissue Factor Antibody-Drug Conjugates
Method for Producing a Controlled Mixture of Two or More Different Antibodies
Method for Producing a Controlled Mixture of Two or More Different Antibodies
Application:
19/045,710 →
Publication:
US US20260132186A1
Methods of Producing Heterodimeric Antibodies
Methods of Producing Heterodimeric Antibodies
Application:
19/302,356 →
Publication:
US US20260139060A1
Methods of Treating Cancer with a Combination of a Platinum-Based Agent and an Anti-Tissue Factor Antibody-Drug Conjugate
Methods of Treating Cancer with a Combination of an Anti-Pd-1 Antibody and an Anti-Tissue Factor Antibody-Drug Conjugate
Application:
18/798,557 →
Publication:
US US20250066507A1
Methods of Treating Cancer with a Combination of an Anti-Vegf Antibody and an Anti-Tissue Factor Antibody-Drug Conjugate
Methods of Treating Cancer with Anti-Tissue Factor Antibody-Drug Conjugates
Application:
18/863,144 →
Publication:
US US20250302982A1
Methods of Treating CD20 Expressing B-Cell Cancers
Application:
18/664,772 →
Publication:
US US20240409656A1
Methods of Treating Lymphoma with Bispecific Antibodies Against CD3 and CD20
Application:
18/633,939 →
Publication:
US US20240368297A1
Modulation of Complement-Dependent Cytotoxicity Through Modifications of the C-Terminus of Antibody Heavy Chains
Modulation of Complement-Dependent Cytotoxicity Through Modifications of the C-Terminus of Antibody Heavy Chains
Monoclonal Antibodies Against CD32B
Monoclonal Antibodies Against CD32B
Monoclonal Antibodies Against C-Met
Monoclonal Antibodies Against C-Met
Monoclonal Antibodies Against C-Met
Monoclonal Antibodies Against C-Met
Application:
17/972,867 →
Publication:
US US20240084036A1
Monoclonal Antibodies Against HER2
Monoclonal Antibodies Against HER2
Monoclonal Antibodies Against HER2
Monoclonal Antibodies Against HER2 Epitope
Monoclonal Antibodies Against HER2 Epitope
Monoclonal Antibodies Against HER2 Epitope
Application:
19/301,104 →
Publication:
US US20260226188A1
Multispecific Antigen-Binding Molecule with Improved Internalization Characteristics
Application:
17/714,735 →
Publication:
US US20230076417A1
Non-Activating Antibody Variants
Application:
18/281,372 →
Publication:
US US20240150484A1
Antibodies Against Human CD38
Application:
19/217,389 →
Publication:
US US20260152566A1
Pharmaceutical Compositions Comprising Antibodies Binding to CD30 and CD3
Application:
19/471,117 →
Pharmaceutical Compositions Comprising Bispecific Antibodies Binding to B7H4 and CD3
Application:
18/289,654 →
Publication:
US US20240383982A1
Pharmaceutical Compositions Comprising Bispecific Antibodies Directed Against CD3 and CD20 and Their Uses
Application:
17/635,258 →
Publication:
US US20220411505A1
Pharmaceutical Compositions Comprising Bispecific Antibodies Directed Against CD3 and CD20 and Their Uses
Application:
16/967,365 →
Publication:
US US20210032358A1
Potency Assays for Antibody Drug Substance Binding to an Fc Receptor
Application:
17/349,482 →
Publication:
US US20220177585A1
Potency assays for antibody drug substance binding to an fc receptor
Production of Heterodimeric Proteins
Production of Heterodimeric Proteins
Production of Heterodimeric Proteins
Application:
17/939,736 →
Publication:
US US20230227495A1
PTK7 Binding Agents, Conjugates Thereof and Methods of Using the Same
Application:
18/897,786 →
Publication:
US US20250115680A1
Recombinant IGG4 Monovalent Antibodies
Recombinant IGG4 Monovalent Antibodies
Recombinant Monovalent Antibodies and Methods for Production Thereof
Rodent Bispecific Heterodimeric Proteins
SLITRK6 Binding Agents, Conjugates Thereof and Methods of Using the Same
Application:
19/016,173 →
Publication:
US US20250296992A1
STABLE IgG4 ANTIBODIES
Method of Treating Cancer or Promoting an Immune Response by Administering a CD38-Binding Antibody Which Induces Trogocytosis-Mediated Reduction of CD38 in CD38-Expressing Immune Cells
Application:
17/259,342 →
Publication:
US US20240254252A1
Variants of CD38 Antibody and Uses Thereof
Application:
18/420,021 →
Publication:
US US20240317881A1
Antibody Variant Combinations and Uses Thereof
Antibody Variant Combinations and Uses Thereof
Antibody Variant Combinations and Uses Thereof
Application:
19/212,413 →
Publication:
US US20260132211A1
Antibody Variants and Uses Thereof
Antibody Variants and Uses Thereof
Antibody Variants and Uses Thereof
Application:
18/741,587 →
Publication:
US US20250043018A1
Antibody Variants and Uses Thereof
Application:
18/816,860 →
Publication:
US US20250223374A1
Anti-Death Receptor Antibodies and Methods of Use Thereof
Application:
17/684,238 →
Publication:
US US20220411522A1
Anti-DR5 Antibodies and Methods of Use Thereof
Anti-DR5 Antibodies and Methods of Use Thereof
Anti-DR5 Antibodies and Methods of Use Thereof
Application:
19/046,332 →
Publication:
US US20260176368A1
Anti-DR5 Family Antibodies, Bispecific or Multivalent Anti-DR5 Family Antibodies and Methods of Use Thereof
Anti-DR5 Family Antibodies, Bispecific or Multivalent Anti-DR5 Family Antibodies and Methods of Use Thereof
Anti-DR5 Family Antibodies, Bispecific or Multivalent Anti-DR5 Family Antibodies and Methods of Use Thereof
Application:
18/461,910 →
Publication:
US US20240141057A1
Dimeric Protein with Triple Mutations
Dimeric Protein with Triple Mutations
Application:
17/012,102 →
Publication:
US US20210230301A1
Humanised Anti-CD52 Antibodies
Methods for the Quantification of Glycoproteins
Application:
17/800,740 →
Publication:
US US20230089196A1
Polypeptide Variants and Uses Thereof
Polypeptide Variants and Uses Thereof
Polypeptide Variants and Uses Thereof
Application:
17/745,667 →
Publication:
US US20230107363A1
Human IGG1 Fc Region Variants and Uses Thereof
Application:
18/744,540 →
Publication:
US US20250145720A1
Polypeptide Variants and Uses Thereof
Application:
18/938,588 →
Publication:
US US20250326854A1
Anti-CD37 Antibodies and Anti-CD20 Antibodies, Compositions and Methods of Use Thereof
Bispecific Anti-CD37 Antibodies, Monoclonal Anti-CD37 Antibodies and Methods of Use Thereof
Bispecific Anti-CD37 Antibodies, Monoclonal Anti-CD37 Antibodies and Methods of Use Thereof
Bispecific Anti-CD37 Antibodies, Monoclonal Anti-CD37 Antibodies and Methods of Use Thereof
Patent:
11,396,553 →
Application:
17/382,758 →
Bispecific Anti-CD37 Antibodies, Monoclonal Anti-CD37 Antibodies and Methods of Use Thereof
Methods of Use of Anti-CD37 Antibodies, Monoclonal Anti-CD37 Antibodies
Related Assignments
(17)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Aug 23, 2010
From: GRAUS, YVO; PARREN, PAUL; VAN DE WINKEL, JAN; DE WEERS, MICHEL
To: GENMAB A/S
Reel/Frame 024873/0306 →
Assignment of Assignor's Interest
Feb 9, 2011
From: DE WEERS, MICHEL; GRAUS, YVO; OPRINS, JUDITH; PARREN, PAUL
To: GENMAB A/S
Reel/Frame 025778/0673 →
Assignment of Assignor's Interest
Dec 17, 2012
From: DE WEERS, MICHEL; WALSETH, TIM; VAN DE WINKEL, JAN; VINK, TOM
To: GENMAB A/S
Reel/Frame 029480/0866 →
Corrective Assignment to Correct the U. S. Provisional Application Number Inside the Assignment Document. Previously Recorded at Reel: 029480 Frame: 0866. Assignor(S) Hereby Confirms the Assignment.
Jul 12, 2016
From: DE WEERS, MICHEL; WALSETH, TIM; VAN DE WINKEL, JAN; VINK, TOM
To: GENMAB A/S
Reel/Frame 040026/0980 →
Assignment of Assignor's Interest
Jul 12, 2016
From: DE WEERS, MICHEL; WALSETH, TIM; VAN DE WINKEL, JAN; VINK, TOM
To: GENMAB A/S
Reel/Frame 039135/0980 →
Assignment of Assignor's Interest
May 31, 2018
From: DE WEERS, MICHEL; WALSETH, TIM; VAN DE WINKEL, JAN; VINK, TOM
To: GENMAB A/S
Reel/Frame 045954/0345 →
Assignment of Assignor's Interest
Dec 6, 2018
From: BREIJ, ESTHER; SATIJN, DAVID; VAN DEN BRINK, EDWARD; VERZIJL, DENNIS
To: GENMAB A/S
Reel/Frame 048552/0528 →
Assignment of Assignor's Interest
Feb 11, 2019
From: BREIJ, ESTHER; SATIJN, DAVID; VAN DEN BRINK, EDWARD; VERZIJL, DENNIS
To: GENMAB A/S
Reel/Frame 048301/0831 →
Assignment of Assignor's Interest
Mar 24, 2021
From: SATIJN, DAVID; BREIJ, ESTHER C. W.; DE GOEIJ, BART E. C. G.; KEMPER, KRISTEL
To: GENMAB A/S
Reel/Frame 055983/0215 →
Assignment of Assignor's Interest
Apr 14, 2021
From: SATIJN, DAVID; BREIJ, ESTHER C. W.; DE GOEIJ, BART E. C. G.; KEMPER, KRISTEL
To: GENMAB A/S
Reel/Frame 055940/0001 →
Assignment of Assignor's Interest
Aug 5, 2021
From: SATIJN, DAVID; BREIJ, ESTHER C. W.; DE GOEIJ, BART E. C. G.; KEMPER, KRISTEL
To: GENMAB A/S
Reel/Frame 057757/0714 →
Assignment of Assignor's Interest
Nov 4, 2021
From: KOOPMAN, LOUISE; ENGELBERTS, PATRICK; VERZIJL, DENNIS; VAN DEN BRINK, EDWARD N.
To: GENMAB A/S
Reel/Frame 058018/0009 →
Assignment of Assignor's Interest
Feb 28, 2023
From: BREIJ, ESTHER; SATIJN, DAVID; VAN DEN BRINK, EDWARD; VERZIJL, DENNIS
To: GENMAB A/S
Reel/Frame 062889/0769 →
Assignment of Assignor's Interest
Aug 18, 2023
From: GRAUS, YVO; PARREN, PAUL; VAN DE WINKEL, JAN; DE WEERS, MICHEL
To: GENMAB A/S
Reel/Frame 064637/0215 →
Assignment of Assignor's Interest
May 1, 2024
From: SATIJN, DAVID; BREIJ, ESTHER C. W.; DE GOEIJ, BART E. C. G.; KEMPER, KRISTEL
To: GENMAB A/S
Reel/Frame 068490/0763 →
Assignment of Assignor's Interest
Mar 4, 2025
From: KOOPMAN, LOUISE; ENGELBERTS, PATRICK; VERZIJL, DENNIS; VAN DEN BRINK, EDWARD N.
To: GENMAB A/S
Reel/Frame 070401/0726 →
Security Interest
Dec 15, 2025
From: GENMAB A/S; GENMAB B.V.; GENMAB HOLDING B.V.
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 073933/0597 →